Efficacy of Combined Peroxisome Proliferator-Activated Receptor-α Ligand and Glucocorticoid Therapy in a Murine Model of Atopic Dermatitis  by Hatano, Yutaka et al.
Efficacy of Combined Peroxisome
Proliferator-Activated Receptor-a Ligand and
Glucocorticoid Therapy in a Murine Model of
Atopic Dermatitis
Yutaka Hatano1, Peter M. Elias2, Debra Crumrine2, Kenneth R. Feingold2,3, Kazumoto Katagiri1 and
Sakuhei Fujiwara1
Although topical glucocorticoids (GCs) show potent anti-inflammatory activity in inflamed skin, they can also
exert numerous harmful effects on epidermal structure and function. In contrast, topical applications of ligands
of peroxisome proliferator-activated receptor-a (PPARa) not only reduce inflammation but also improve
cutaneous barrier homeostasis. Therefore, we examined whether sequential topical GCs followed by topical
Wy14643 (a ligand of PPARa) might be more effective than either alone for atopic dermatitis (AD) in a hapten
(oxazolone (Ox))-induced murine model with multiple features of AD (Ox-AD). Despite expected anti-
inflammatory benefits, topical GC alone induced (i) epidermal thinning; (ii) reduced expression of involucrin,
loricrin, and filaggrin; and (iii) allowed outside-to-inside penetration of an epicutaneous tracer. Although
Wy14643 alone yielded significant therapeutic benefits in mice with mild or moderate Ox-AD, it was less
effective in severe Ox-AD. Yet, topical application of Wy14643 after GC was not only significantly effective
comparable with GC alone, but it also prevented GC-induced structural and functional abnormalities in
permeability barrier homeostasis. Moreover, rebound flares were largely absent after sequential treatment with
GC and Wy14643. Together, these results show that GC and PPARa ligand therapy together is not only effective
but also prevents development of GC-induced side effects, including rebound flares, in murine AD.
Journal of Investigative Dermatology (2011) 131, 1845–1852; doi:10.1038/jid.2011.144; published online 2 June 2011
INTRODUCTION
Two major pathological features of atopic dermatitis (AD)
are cutaneous permeability dysfunction and allergic inflam-
mation, which drive each other in a classic vicious cycle
(Elias et al., 2008). Therefore, treatment of AD ideally should
incorporate methods that address both of these disease
components. Topical glucocorticoids (GCs) have potent
anti-inflammatory effects, and represent standard treatment
for AD, particularly in severe cases. However, improvement
of AD symptoms comes at a price. As inflammation recedes,
numerous harmful effects on epidermal structure and func-
tion emerge, which, in turn, could account for the commonly
observed clinical phenomena of tachyphylaxis and rebound
flare-ups following cessation of GC therapy (Hiratsuka et al.,
1996; Fukaya, 2000; Kawakami et al., 2001). Specifically,
GCs abrogate cutaneous permeability barrier homeostasis
(Kao et al., 2003); suppress expression of epidermal anti-
microbial peptide (Aberg et al., 2007); inhibit the expression
of epidermal differentiation-linked structural proteins, such as
involucrin, filaggrin, and loricrin (Demerjian et al., 2009);
and inhibit epidermal proliferation in normal skin. Skin
atrophy (Schacke et al., 2002), therefore, results not only from
the loss of dermis, but also as a consequence of multiple
negative effects on epidermis.
Activators of peroxisome proliferator-activated receptors
(PPARs) a, b/d, and g, and liver X receptors (LXRs), which
belong to the superfamily of nuclear hormone receptors,
display potent, but largely positive effects on epidermal
structure and function in normal and diseased skin (reviewed
in Schmuth et al., 2008). Earlier studies have shown that
PPAR and LXR activators show substantial anti-inflammatory
activity in murine models of both irritant and acute allergic
contact dermatitis (Sheu et al., 2002; Fowler et al., 2003), and
reverse epidermal hyperplasia while normalizing epidermal
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differentiation in a hyperproliferative disease model in mice
(Komuves et al., 2000a, b). These earlier results suggest that
PPAR and LXR activators could mitigate several features
of inflammatory dermatoses; and conversely, that their
activators could be useful for the treatment of such diseases,
including AD. Expression of PPARa is reduced in atopic
lesional skin, and topical treatment with a PPARa activator
prevents emergence of murine AD (Staumont-Salle et al.,
2008), suggesting that a reduction in PPARa signaling might
contribute to the pathogenesis of AD. More recently, we
showed that topical activators/ligands of PPARa show potent
anti-inflammatory benefits in another murine model of
AD (Hatano et al., 2010).
Co-treatment with certain PPAR activators reverses a
variety of adverse effects of the topical GC treatment on
normal murine epidermis (Demerjian et al., 2009); namely,
co-applications of a PPARa ligand normalized the expression
of differentiation-linked structural proteins (involucrin, filag-
grin, and loricrin); keratinocyte proliferation and epidermal
thickness; and permeability barrier homeostasis. Therefore,
we postulated that combination treatment of AD with both
GC and a PPARa activator could be not only at least as
effective as treatment with GC alone, but that it also could
prevent emergence of GC-related epidermal side effects.
Thus, in this study, we compared the efficacy of sequential
combination therapy with a super-potent GC (clobetasol) plus
a PPARa ligand with the GC and PPARa ligand alone. We
chose PPARa, rather than a PPARb/d or LXR ligand, as our
therapeutic target, because first, more is known about its
potential role in the pathogenesis of AD (Staumont-Salle
et al., 2008), and because certain PPAR activators improve
inflammation and barrier function in our previously estab-
lished hapten-induced murine model of AD (Man et al.,
2008). We report here that the treatment with the activator of
PPARa ligand, Wy14643, by itself, significantly improves
mild-to-moderate disease but is less effective in more severe
dermatitis. Second, we found that the treatment with the
super-potent GC, with Wy14643 not only was highly
effective, even in severe dermatitis, but it also prevented
the emergence of GC-induced epidermal side effects and
rebound flares of dermatitis.
RESULTS
Efficacy of the PPARa activator, super-potent GC, and
combination therapy
We first examined the efficacy of clobetasol propionate,
a super-potent GC, and Wy14643 in oxazolone (Ox)-AD
mice with features of AD of increasing severity, assessed as
changes in clinical appearance, histological features, T-cell
infiltration, and basal TEWL. (Recent studies have demon-
strated that TEWL correlates well with clinical (inflammatory)
status in AD; Sugarman et al., 2003; Angelova-Fischer
et al., 2005.) Topical application of Wy14643 alone for
4 days improved clinical appearance and reduced TEWL in
Ox-AD mice with ‘‘moderate’’ dermatitis (initial TEWL values
p25 gm2 per hour), but exacted little effects in Ox-AD mice
with initial TEWL values X25 gm2 per hour (Figure 1a).
By contrast, topical application of clobetasol propionate
alone for 4 days was uniformly effective, even in animals with
severe dermatitis. Although topical application of Wy14643
alone for 4 days was less effective than GC alone for severe
Ox-AD, the sequential combination of GC plus Wy14643
(i.e., experimental day 1, GC alone; from day 2 to day 4,
Wy14643 alone) reduced TEWL even when lesions were
severe, and it did so to the same extent as GC alone. The
sequential combination of GC plus vehicle was not effective
for severe dermatitis (Figure 1b). In parallel with alterations of
TEWL, infiltration of CD3-positive cells also declined after
treatment either with GC alone or with the sequential com-
bination of GC and Wy14643. Infiltration of CD3-positive
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Figure 1. Effects of treatment with a topical glucocorticoid (GC) and/or a peroxisome proliferator-activated receptor-a activator on transepidermal
water loss (TEWL) and the infiltration of CD3-positive cells. Transepidermal water loss (a and b) was measured as described in the text. In b and c, Ox-AD mice,
in which TEWL was 425 gm2 per hour on day 1, were used for the experiments. *Po0.05 versus day 1. Numbers of CD3-positive cells on day 5 are shown
in c. n¼ 8 (four mice) in a, n¼ 6–10 (three to five mice) in b, and n¼40–80 (three to four mice) in c. Ox, oxazolone; veh, vehicle; Wy, Wy14643.
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cells also declined after treatment with the combination of
GC and vehicle (Figure 1c), but to a lesser extent than either
GC alone or the combination of GC and Wy14643.
The sequential combination of GC and the PPARa activator did
not show any emergence of GC-induced epidermal side effects
In parallel with the apparent therapeutic benefits described
above, GC alone and the sequential combination of GC plus
Wy14643 significantly normalized epidermal hyperplasia in
Ox-AD mice, whereas, in contrast, thinning of the epidermis
was readily apparent in Ox-AD mice that had been treated
with GC alone (Figure 2). In contrast, lesions treated with
the sequential combination of GC and Wy14634 did not
show epidermal thinning (Figure 2). As reported previously
(Man et al., 2008), expression of three differentiation-linked
structural proteins (involucrin, loricrin, and filaggrin) was
abnormal and/or reduced in the outer epidermis of Ox-AD
mice, and GC alone further reduced expression of these
proteins (Supplementary Figure 1S online). Yet, expression of
the differentiation-linked proteins normalized after sequential
treatment with GC and Wy14643.
The sequential combination of GC and the PPARa activator
showed superior permeability barrier homeostasis to GC alone
We used three different methods to assess the changes in
permeability barrier status in treated Ox-AD mice. A
quantitative, dye-penetration assay revealed that ‘‘outside-
to-inside’’ permeability improved significantly in lesions that
had been treated with the sequential combination of GC and
Wy14643 but not in lesions that had been treated with GC
alone (Figure 3a). Results with the electron-dense tracer,
lanthanum nitrate, for ‘‘inside-to-outside’’ penetration assess-
ment supported the dye penetration assay (Figure 3b–d).
Finally, we compared the kinetics of recovery of permeability
barrier function (% change in TEWL over time) at the end
of each type of treatment; i.e., on experimental day 5, at
48 hours after the last Ox challenge dose. As shown in
Figure 1b, values of TEWL at the end of the treatment period
were similar in Ox-AD mice that had been treated with the
sequential combination of GC and Wy14643 versus sites
treated with GC alone (Figure 4a). However, at 24 hours after
further acute abrogation of the barrier by tape stripping,
TEWL declined to normal levels in Ox-AD mice that had
been treated with the combination of GC and the PPARa
activator, whereas TEWL remained higher than normal at
48 hours after tape stripping in Ox-AD mice that had been
treated with GC alone (Figure 4a). Accordingly, barrier
recovery was greater in Ox-AD mice that had been treated
with the sequential combination of GC and PPARa activator
than it was in Ox-AD mice that had been treated with GC
alone at each time point examined (Figure 4b).
The sequential combination of GC and the PPARa ligand
prevents rebound flares of Ox-AD
We examined whether sequential application of GC and
Wy14643 protects Ox-AD mice against the development of
rebound flares, which are observed after treatment with GC
alone. Eczematous lesions reappeared in mice within 4 days
after discontinuation of treatment with GC alone. In contrast,
re-development of such lesions was significantly reduced in
Ox-AD mice that had been treated sequentially with GC plus
Wy14643 (Figure 5a). In parallel with these clinical obser-
vations, we found that both basal TEWL levels and the
infiltration of CD3-positive cells were higher in mice treated
with GC alone than in mice that had been treated with the
sequential combination of GC and Wy14643 (Figure 5b
and c). These results show that the application of the PPARa
activator after application of GC inhibits the re-emergence
(¼ rebound flares) that occurs after termination of treatment
of Ox-AD with GC alone.
DISCUSSION
Immunological abnormalities and skin barrier dysfunction
both contribute to the pathogenesis of AD (Elias et al., 2008),
and effective therapy should address both these issues.
Treatment with PPARs and LXRs ligands seems promising
because these agents not only have anti-inflammatory activity
but they also show positive effects on cutaneous permeability
barrier homeostasis (Sheu et al., 2002; Fowler et al., 2003;
Schmuth et al., 2008; Fluhr et al., 2009). Some ligands of
PPARa, b/d (but not g), and LXR, including the PPARa ligand
Wy14643, have been shown to be effective in the murine
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Figure 2. Morphological changes in the epidermis. Skin samples were collected on experimental day 5 and were stained with hematoxylin and eosin
as shown in a. Bars¼ 20 mm. Epidermal thickness was measured as described in the text and is shown in b. n¼30–60 (three to four mice). Ox, oxazolone;
veh, vehicle; Wy, Wy14643.
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model of AD used in this study (Hatano et al., 2010), and
involvement of PPARa in the pathogenesis of AD has been
suggested from studies in another murine model of AD
(Staumont-Salle et al., 2008). However, the PPARa ligand
by itself showed limited therapeutic efficacy in severe lesions
in our AD model, presumably reflecting its lower anti-inflam-
matory potency in comparison with the ‘‘super-potent’’ GC,
clobetasol propionate. Yet, the potency of GC comes at a price,
because important side effects appear as inflammation recedes.
Demerjian et al. (2009) recently demonstrated that PPARa
ligands prevent the epidermal abnormalities that are induced
by super-potent GC, such as epidermal thinning and aberrant
permeability barrier homeostasis. Therefore, we postulated
that the combination of GC plus a PPARa ligand could prove
more effective and safer for the treatment of AD than
treatment with either agent alone. Although the sequential
combination of GC and Wy14643 was as effective for severe
dermatitis lesions as GC alone, epidermal thinning, which
was prominent after treatment with GC alone, was not
observed after co-treatment of severe dermatitis with GC
plus Wy14643. In addition, the reduction in the expression
of three differentiation-linked structural proteins, namely,
involucrin, loricrin, and filaggrin, induced during GC therapy
alone, was prevented by the sequential application of GC and
Wy14643, echoing previous results in similarly co-treated
normal mouse skin (Demerjian et al., 2009). Thus, it seems
that the sequential applications of GC and the PPARa ligand
not only maintains therapeutically efficacy but it also blunts
the harmful effects of GC alone on epidermal structure and
function.
Both the quantitative, dye penetration assay and ultrastruc-
tural observations of lanthanum permeation revealed that
barrier function is restored by co-treatment with the combina-
tion of GC and Wy14643, but not by GC alone. The beneficial
effects of the sequential combination treatment on barrier
homeostasis were consistent with the observed normalization
of the expression of epidermal differentiation-linked structural
proteins. Consistent with the abundant evidence that activators
of PPARa have positive effects on barrier homeostasis
(Schmuth et al., 2008), barrier recovery was also enhanced
by sequential application of GC and Wy14643. Together these
observations on barrier homeostasis likely account for the
demonstrated ability of the PPARa ligand to prevent exacer-
bation of AD symptoms after discontinuation of GC therapy.
Taken together, the results of this study suggest that
combined sequential treatment with GC and Wy14643 could
provide greater therapeutic benefits than treatment of
AD with GC alone. Previous efforts to reduce the adverse
effects of topical GC on cutaneous structure and func-
tion have involved moisturizers (Chamlin et al., 2002; Cork
et al., 2003; Wire´n et al., 2009), topical calcineurin inhi-
bitors (Meurer et al., 2002; Furue et al., 2004), and an
oral antihistamine, olopatadine hydrochloride (Tamura et al.,
2005), both in patients with AD and in murine AD models.
However, PPARa ligands, such as Wy14643, could appear to
provide a superior choice for the prevention of the adverse
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Figure 3. Assessment of outside-to-inside permeability barrier function. The results of a quantitative penetration assay with Evans blue (a; n¼ 8 (four mice))
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effects of topical GC, because PPARa ligands have both anti-
inflammatory effects and potent positive effects on cutaneous
barrier homeostasis (Komuves et al., 2000a, b; Sheu et al.,
2002; Fluhr et al., 2009). Moisturizers have less anti-inflam-
matory activity than PPARa activators, and while topical
calcineurin inhibitors show significant anti-inflammatory
effects, they compromise both epidermal permeability barrier
functions and antimicrobial barrier function in mice (Kim
et al., 2010). The oral administration of olopatadine hydro-
chloride has a positive effect on permeability barrier homeo-
stasis and inflammation (Amano et al., 2007; Tamura et al.,
2008), an observation that is consistent with the known
ability of antihistamines (H1 and H2 blockers) to improve
barrier function (Ashida et al., 2001). However, it remains to
be determined whether topical administration of olopatadine
hydrochloride would also be effective for the treatment of
AD, and in addition, it is unclear whether they can prevent
the emergence of GC-related side effects.
According to the ‘‘outside–inside’’ view of AD patho-
genesis (Elias et al., 2008), normalization of barrier function
should reduce the two major drivers of inflammation in AD,
namely, the generation of cytokines that originate from
perturbed corneocytes, and the transepidermal penetration of
pro-inflammatory xenobiotes, such as haptens and microbial
pathogens. Indeed, rebound flare-up was prevented only in
Ox-AD mice, in which the permeability barrier had been
restored by sequential treatment with GC and the PPARa
ligand. Thus, agents that have positive effects on permeability
homeostasis should help us to prevent the negative effects of
topical GC, including rebound flare-up.
70
60
50
P=0.003
Normal
Ox+GC, GC
Ox+GC, GC
Ox+GC, WY
P=0.005
P=0.006
P=0.01 P=0.03140
120
100
Ba
rri
er
 re
co
ve
ry
 (%
)
80
60
40
20
0
Ox+GC, Wy
P=0.002
P=0.001
P=0.001
40
TE
W
L 
(g 
m–
2  
pe
r h
ou
r)
30
20
10
0
Before After 3 Hours 6 Hours 24 Hours 48 Hours
3 Hours 6 Hours 24 Hours 48 Hours
Figure 4. Recovery of permeability barrier function. On experimental day 5,
the permeability barrier was disrupted by tape stripping as described in the
text. Transepidermal water loss (TEWL) was examined before and after tape
stripping, at each indicated time point, as described in the text. The horizontal
dotted line indicates the mean values in normal control mice. The P-values
in a refer to the differences between OxþGC, GC and OxþGC, Wy.
n¼ 10 (five mice). Ox, oxazolone; veh, vehicle; Wy, Wy14643.
Ox+GC, GC
Ox+GC, GC
Ox+GC, Wy
Ox+GC, Wy
P = 0.0019
35
30
TE
W
L 
(g 
m–
2  
pe
r h
ou
r)
25
20
Ox+GC, GC
Ox+GC, WY
15
10
Day 1
Ox+GC, GC:
Ox+GC, Wy:
Ox
GC
GC
GC
Wy Wy
GC GC
Wy
Ox Ox Ox
Day 3 Day 5 Day 7 Day 9
P <0.000001
20
18
N
um
be
r/2
50
 m
m
×
 
25
0 
m
m
16
14
12
10
8
6
4
2
0
Figure 5. Rebound of dermatitis after discontinuation of therapy. The every-other-day skin challenge with Ox alone was continued (day 5 and day 7)
on the same area without GC nor Wy treatment. (a) Clinical appearance of mice on experimental day 9. (b) Alteration of transepidermal water loss (TEWL).
(c) Density of CD3-positive cells in skin samples collected on day 9. The P-values refer to results from OxþGC, GC and OxþGC, Wy. n¼ 12 (six mice)
in b; n¼ 24 (three mice) for GC, GC in c; and n¼ 26 (three mice) for GC, Wy in c. Ox, oxazolone; veh, vehicle; Wy, Wy14643.
www.jidonline.org 1849
Y Hatano et al.
Beneficial Treatment in Atopic Dermatitis
In conclusion, this study suggests that the sequential
combination of topical GC and a PPARa ligand, Wy14634,
might be an effective strategy for the treatment of human AD.
The activators of PPAR or LXR, which are most suitable for
application with GC, remain to be identified before this
therapeutic strategy can be tested in a clinical setting. Finally,
our study suggests that the Ox-AD mouse model might be
useful for assessment of mechanisms involved in rebound
flare-ups.
MATERIALS AND METHODS
Animals and materials
Female hairless (Hr-/Kud) mice (Kyudo, Fukuoka, Japan) were used
at 12–48 weeks of age. All animals were housed under conventional
conditions, and had free access to a commercial diet and water.
WY14643 (PPARa activator), clobetasol propionate, Ox, MCDB
153, Evans blue, and lanthanum nitrate were purchased from Sigma
Chemical (St Louis, MO). Affinity-purified rabbit primary antibodies,
specific, respectively, for mouse filaggrin, loricrin, and involucrin,
were purchased from BabCo (Richmond, CA). Biotinylated second
antibodies, raised in goat against rabbit IgG, and an ABC-peroxidase
kit were purchased from Vector Laboratories (Burlingame, CA).
A rabbit anti-human antibody against CD3 was purchased from
Dako (Glostrup, Denmark).
Development and treatment of hapten-induced dermatitis with
features of AD in mice
All animal procedures were approved by the ‘‘Ethics of Animal
Experimentation Committee’’ of Oita University. Development of a
hapten (Ox)-induced, murine model with multiple features of AD
(Ox-AD) was described in our previous studies (Man et al., 2008;
Hatano et al., 2010). Animals were sensitized by 2 consecutive days
of topical treatment with 50 ml of 5% Ox in acetone. After 1 week,
mice were treated topically on both flanks with 60ml of 0.5% Ox in
ethanol once every other day for an additional 4 weeks (total of
12 challenges). To achieve more severe lesions, the concentration of
Ox used for elicitation of AD was higher than that (i.e., 0.1%) used in
our previous studies (Man et al., 2008; Hatano et al., 2010). After the
10th challenge, when the phenotype of AD-like chronic allergic
dermatitis had been established, the therapeutic effects of a topical
super-potent class 1 GC, namely, clobetasol propionate, and of a
synthetic PPARa ligand, namely, Wy14643, were assessed by the
method described in our previous report (Hatano et al., 2010) and
as described in the legend to Table 1. At 1 hour after the 11th
challenge, twice-daily applications of 60ml of 10mM WY14643 in
the vehicle of 0.05% clobetasol propionate in the vehicle or of
vehicle alone (a mixture of propylene glycol and ethanol, 7:3, v/v)
were given for 4 days until experimental day 4. The 12th challenge
with Ox was administered at 1 hour before the first application
of GC, Wy14643, or vehicle on that day. As shown in Table 1,
in some experimental groups, GC, Wy14643, or vehicle was
applied for 4 consecutive days and in other groups, GC was applied
only on the first day of the experiment, with 3 subsequent
consecutive days of treatment with Wy14643 or vehicle. In some
experiments, applications of Ox alone (i.e., without GC,
Wy14643, or vehicle) were continued on the same areas on
experimental day 5 and day 7 after therapeutic procedures had
been discontinued.
Measurement of permeability barrier function
Basal transepidermal water loss (TEWL) was measured on individual
flanks with a skin-evaporative water recorder (Tewameter TM210;
Courage & Khazawa, Koln, Germany) immediately before each
application of Ox and at 48 hours after the final application of Ox.
The kinetics of permeability barrier recovery were examined as
described previously (Kurahashi et al., 2008). Barrier disruption was
achieved by sequential applications of cellophane tape (Nichiban,
Tokyo, Japan). The procedure was stopped when TEWL reached
52–62 gm2 per hour, as measured with the skin evaporative water
recorder. Barrier recovery was monitored immediately after and at
3, 6, 24, and 48 hours after further disruption of sites of skin lesions.
Recovery rates were calculated as described previously (Hou et al.,
1991).
Immunohistochemistry
Full-thickness skin was harvested for immunohistochemical staining
of filaggrin, loricrin, involucrin, and for counting of CD3-positive
T cells at 48 hours after the last application of Ox. Immunohisto-
chemical staining was carried out as described previously (Man
et al., 2008; Hatano et al., 2009). In brief, 5-mm paraffin-embedded
sections were incubated with primary antibodies overnight at 4 1C.
After three washes, sections were incubated with second antibodies
for 30minutes. Staining was detected with the ABC-peroxidase kit.
Quantitative morphology
The number of CD3-positive cells in a 250mm 250mm area of
dermis was determined inX40 fields of dermis in each experimental
group. The thickness of layers of epidermal nucleated cells, as
observed in sections stained with hematoxylin and eosin, was
measured at X30 points, at intervals of 200 mm, in each experi-
mental group. These quantitative morphological examinations were
performed under the condition in which an investigator could not
find each sample belong to which experimental group.
Quantitative evaluation of outside-to-inside barrier function
Quantitative evaluation of outside-to-inside penetration of the skin
was assessed with Evans blue dye. Skin samples, 16mm in diameter,
were collected from flanks at 48 hours after the last application of
Ox and each sample was floated on MCDB 153 medium that
contained 1.8mM CaCl2 with the outer epidermal surface of each
Table 1. Treatment of hapten-induced atopic
dermatitis in a murine model
Experimental
group
Day 1
(11th Ox) Day 2
Day 3
(12th Ox) Day 4
Ox+veh veh veh veh veh
Ox+Wy, Wy Wy Wy Wy Wy
Ox+GC, GC GC GC GC GC
Ox+GC, veh GC veh veh veh
Ox+GC, Wy GC Wy Wy Wy
Abbreviations: GC, glucocorticosteroid; Ox, oxazolone; veh, vehicle; Wy,
Wy14643.
See text for details. This table indicates the experimental groups in this
study.
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sample exposed to the air. Then 100 ml of 2% Evans blue in
phosphate-buffered saline were pipetted onto the outer epidermal
surface of each skin explant. The dye was allowed to penetrate the
skin for 4 hours at room temperature, and then the surface of the skin
was washed with phosphate-buffered saline and gently wiped with a
Kimwipe (Nippon Paper Crecia, Tokyo, Japan). After the washing
procedures had been repeated three times, the center of each
explant was biopsied with a 4-mm punch and each 4-mm disk was
placed into 100 ml of 1 N KOH. After overnight incubation at 37 1C,
each sample was neutralized by the addition of 900ml of a mixture
of 0.6 N H3PO4 and acetone (5:13, v/v). After vigorous vortexing
for a few seconds, the mixture was centrifuged at 3,000 r.p.m. for
15minutes in Kubota RA-150AM (Kubota, Tokyo, Japan) and
absorbance of supernatants was measured at 360 nm.
Electron microscopic observations of lanthanum nitrate
penetration
The penetration of an electron-dense, water-soluble, low-molecular-
weight tracer, lanthanum nitrate, from the outside toward the inside
of the skin was assessed as described previously (Scharschmidt et al.,
2009). In brief, skin samples, 16mm in diameter, were collected
from flanks at 48 hours after the last application of Ox, and each
sample was floated on MCDB 153 medium that contained 1.8mM
CaCl2, with the outward facing, epidermal side of each sample
exposed to air. Then 100ml of 4% lanthanum nitrate in phosphate-
buffered saline were pipetted onto the outer epidermal surface of
each explant. The dye was allowed to penetrate the skin for 3 hours
at room temperature. Then aldehyde-fixed biopsy specimens were
fixed in either 0.25% ruthenium tetroxide or 1% aqueous osmium
tetroxide that contained 1.5% potassium ferrocyanide, as described
previously (Hou et al., 1991). Ultrathin sections were examined with
an electron microscope (Zeiss 10A; Carl Zeiss, Thornwood, NY)
operated at 60 kV. Images were captured with Digital Micrograph
3.10.0 software (Gatan, Pleasanton, CA).
Statistical analysis
The statistical significance of differences was evaluated by Student’s
t-test under normal distribution. A value of Po0.05 was considered
statistically significant. Each result is given as a mean value±SE,
with the number of samples, n.
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